Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis.

Stem Cell Res Ther · 2019 · PMC6528271 · PMID 31109372

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = 0.09so close (0.05 < p ≤ 0.1)

Clinical outcomes Compared with controls, BMC therapy had a tendency to reduce the incidence of MACE and rehospitalization; however, the results did not reach statistical significance, with RR of 0.79 (95% CI 0.59 to 1.04, P = 0.09, I 2 = 0%) and 0.71 (95% CI 0.49 to 1.04, P = 0.08, I 2 = 0%), respectively (Table 2 ).

also in 111,027 other papers

a clear trendno p-value reported

However, the outcomes showed a clear trend in favor of the BMC group.

also in 19,460 other papers

showed a trendno p-value reported

Results showed a trend towards a decrease in MACE and rehospitalization in BMC patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.